Urology Doctors in Hendersonville, NC Accepting Medicare

4 Urology doctors found. Showing 1 - 4

Clifford Paul Johnson, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 50 Hospital Dr, Suite 2a, Hendersonville, NC 28792 Phone: 828-654-6015    Fax: 828-687-6058

J. David Deholl Jr., MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1216 6th Ave W, Hendersonville, NC 28739 Phone: 828-692-6262    Fax: 828-692-5858

Dr. Andrew Howard Krueger, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 50 Hospital Dr, Suite 2a, Hendersonville, NC 28792 Phone: 828-654-6015    Fax: 828-687-6058

Dr. Richard Benjamin Moore Jr., M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 22 Delacy Dr, Hendersonville, NC 28739 Phone: 828-697-0754

News Archive

BlueCross, SodexoMAGIC holds an end-of-summer barbeque for Chattanooga youth

Volunteers from SodexoMAGIC, LLC and BlueCross BlueShield of Tennessee will hold an end-of-summer barbeque for Chattanooga youth today, celebrating the service of nearly 21,000 free summer lunches this year funded by a Feeding Our Future grant from the Sodexo Foundation.

Testosterone has measurable effect on a man's preference for brands

Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.

Patients without advance care plans more likely to die

Researchers at the University of Nebraska Medical Center (UNMC) in Omaha and the Fred Hutchinson Cancer Research Center in Seattle found only half of patients undergoing stem cell transplantation had advance care plans - documents such as living wills, power of attorney for health care, or life-support instructions - and those without plans were three times more likely to die during or after surgery.

OncoSec enrolls first patient in Phase II trial of ImmunoPulse IL-12 for treatment of HNSCC

OncoSec Medical Inc., a company developing DNA-based intratumoral cancer immunotherapies, announced today that the company has enrolled the first patient into OMS-I130, a Phase II clinical trial of ImmunoPulse IL-12 in patients with treatment-refractory, metastatic and unresectable squamous cell carcinoma of the head and neck (HNSCC).

International Stem Cell, IBVI sign letter of intent concerning funding, establishment of ISCO India

International Stem Cell Corporation, www.internationalstemcell.com, and Insight Bioventures India Private Limited, announced today that they have signed a letter of intent concerning funding and establishment of an Indian affiliate of ISCO. The goal is to establish world-class development and manufacturing operations for ISCO's research and pharmaceutical products in India, including its Lifeline Cell Technology research products and human corneal tissue, CytoCor, for treatment of corneal vision impairment and testing of chemicals.

Read more Medical News

› Verified 8 days ago